# Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

> **NCT04815083** · PHASE3 · TERMINATED · sponsor: **SBI ALApharma Canada, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Breast Neoplasm Female
- Breast Cancer

## Interventions

- **DRUG:** Aminolevulinic Acid Hydrochloride
- **DEVICE:** Eagle V1.2 Imaging System
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04815083
- **Lead sponsor:** SBI ALApharma Canada, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-27
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-12-20
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Study terminated due to closure of Sponsor business
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04815083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04815083, "Fluorescence Imaging of Carcinoma During Breast Conserving Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04815083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*